Spectranetics Beats on EPS but GAAP Results Lag
Spectranetics (NAS: SPNC) reported earnings on Feb. 16. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Spectranetics beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped to a loss.
Gross margins increased, operating margins improved, and net margins dropped.
Spectranetics notched revenue of $32.5 million. The five analysts polled by S&P Capital IQ looked for sales of $31.9 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $29.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.04. The six earnings estimates compiled by S&P Capital IQ predicted $0.02 per share on the same basis. GAAP EPS were -$0.06 for Q4 versus $0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.9%, 240 basis points better than the prior-year quarter. Operating margin was 5.7%, 80 basis points better than the prior-year quarter. Net margin was -6.2%, 800 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $32.5 million. On the bottom line, the average EPS estimate is $0.01.
Next year's average estimate for revenue is $135.6 million. The average EPS estimate is $0.09.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 158 members out of 170 rating the stock outperform, and 12 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Spectranetics a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Spectranetics is buy, with an average price target of $10.46.
The health-care investing landscape is littered with also-rans and a few major winners. Is Spectranetics performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Spectranetics to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.